PregnanTech

Preterm Birth Prevention

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in January 2017 by David Shashar and Avi Tsur, PregnanTech operates with 1–10 employees. The company has secured funding across 5 rounds from 6 investors.

Business overview

PregnanTech is a Health Tech & Life Sciences company focused on preventing preterm birth. The company develops the Lioness, a small, disposable device designed to maintain the natural resistance of the cervix. This device acts as a shock absorber, allowing transient cervical changes during contractions and then restoring the cervix to its initial state. PregnanTech serves the healthcare industry, specifically targeting women's health, gynecology, and medical device markets.

Strategic signal

In July 2024, PregnanTech's efforts to address the preterm birth crisis were highlighted, signaling a potential new hope in this critical area of women's health. This indicates ongoing progress and validation of their Lioness device, suggesting a positive trajectory for clinical development and market entry, which is a strong signal for investors interested in impactful medical innovations.

Log in to access full profile

Company Intelligence Q&A

What is PregnanTech's primary product?
PregnanTech's primary product is the Lioness, a small, disposable device designed to prevent preterm birth by maintaining the natural resistance of the cervix.
When was PregnanTech founded and by whom?
PregnanTech was founded in January 2017 by David Shashar and Avi Tsur.
What was the focus of PregnanTech's clinical studies in 2019?
In 2019, PregnanTech began a clinical safety study of the Lioness device among non-pregnant women intended for hysterectomy, demonstrating significant potential.
Log in to access full profile